The Functional Communication Checklist for People Living with Primary Progressive Aphasia: Study Protocol

3

Jeanne Gallée¹, PhD; Jade Cartwright², PhD; Maya L Henry³, PhD; Aimee Mooney⁴,
MS; Brielle C Stark⁵, PhD; Anna Volkmer⁶, PhD; Connie Nakano¹, MPH; Rob J
Eredericksen⁷, PhD; Kimiko Domoto Pailly⁸, MD, MS; Paul K Grand, MD, MDU

- 6 Fredericksen⁷, PhD; Kimiko Domoto-Reilly⁸, MD, MS; Paul K Crane¹, MD, MPH
- 7
- 8 9
- ¹Department of Medicine, University of Washington, Seattle, WA, United States of America
- 12 ²School of Health Sciences, University of Tasmania, Launceston, Australia
- ¹³ ³Department of Speech, Language, and Hearing Sciences, University of Texas-Austin,
- 14 Austin, TX, United States of America
- ⁴Department of Neurology, Oregon Health & Science University, Portland, OR, United
- 16 States of America
- ⁵Department of Speech, Language, and Hearing Sciences, Indiana University,
- 18 Bloomington, IN, United States of America
- ⁶Division of Psychology and Language Sciences, University College London, London,
- 20 United Kingdom
- 21 ⁷Department of Allergy and Infectious Diseases, University of Washington, Seattle, WA,
- 22 United States of America
- ⁸Department of Neurology, University of Washington, Seattle, WA, United States of
- 24 America
- 25
- 26
- 27 Corresponding Author: Jeanne Gallée, BA, PhD
- 28 Department of Medicine
- 29 University of Washington
- 30 Harborview Medical Center
- 31 325 9th Avenue
- 32 Seattle, WA 98104
- 33 United States of America
- 34 Phone: +1 (425)-246-5579
- 35 Email: jgallee@uw.edu

37

- 39 centered
- 40
- 41
- 42

³⁶

³⁸ Keywords: assessment; functional communication; primary progressive aphasia; person-

43 Abstract

44	This study protocol describes the development of the first instrument of functional
45	communication for people living with primary progressive aphasia (PPA), with future
46	applications to other progressive conditions, with expert validation, item-level reliability
47	analyses, and stakeholder input and outcomes. Progressive conditions like PPA require
48	monitoring, and as such, re-assessment. Re-assessment poses the high risk of being
49	burdensome, destructive, and of little use to the patient. As such, there is a significant
50	need to establish a validated and reliable measure that (1) poses minimal patient burden
51	and (2) captures communication ability in a strengths-based manner that is representative
52	of daily communication needs and challenges. A strengths-based approach to assessment
53	is widely recognized as the optimal way to promote patient autonomy, minimize harm,
54	and implement functional treatment protocols and strategies. To date, there are no
55	strengths-based assessment tools that were developed for people living with PPA. This
56	study protocol describes our work to address this gap in clinical practice and research.
57	
58	
59	
60	
61	
62	
63	
64	
65	

66 1 Introduction

67	Fifty thousand Americans are currently estimated to be living with primary
68	progressive aphasia (PPA)[1], a clinical syndrome that initially presents with focal
69	language decline and is typically attributable to pathological findings consistent with
70	frontotemporal degeneration or Alzheimer's disease (AD) [2-5]. People living with PPA
71	(PwPPA) experience progressive decline in focal aspects of speech, language, and
72	communication in the mild to moderate stages [2-5]. To date, there are three PPA variants
73	established in the literature: the nonfluent/agrammatic, semantic, and logopenic with
74	differentiated syndromic characteristics (see Table 1) [2-5].
75	To receive a PPA diagnosis, a person must experience prominent difficulty with
76	speech and language at symptom onset that is the principal source of disrupted
77	functioning and that is attributable to neurodegenerative disease [2-4]. PPA causes
78	important changes in functional communication (FC), which is defined as the
79	"transactional success" of expression [6], and which is a fundamental feature of human
80	connection [7]. FC ability in PPA diverges by variant, individual differences, and time
81	[5,8-10]. A person-centered approach—a holistic and humanistic method that promotes
82	the autonomy and needs of the patient—is integral to establish how individual differences
83	can impact a person's success in FC [9,11] and to deliver individualized care [9,12].
84	

85	PPA is a devastating, but relatively rare, condition [1]. As a result, a "gold
86	standard" approach to care remains to be established [8]. Clinical assessment is essential
87	to accurately identify and to formulate a specific diagnosis of PPA, and efficiently lead to
88	treatment recommendations and post-diagnostic supports; however, to date, assessment
89	procedures and documentation protocols are non-standardized or non-specific to this
90	population [8,11]. These significant limitations have adverse effects on the accuracy and
91	efficiency of diagnostic formulation and assessment outcomes, and result in irregularities
92	in clinical evaluation protocols and cross-institutional characterization of research

93 cohorts.

94 Table 1. The Primary Symptoms of the Established PPA Variants.

Variant	Primary Symptoms at Onset ¹⁻⁵
Nonfluent/agrammatic	Impaired motor speech planning and
	syntax
Semantic	Loss of object knowledge, confrontation
	naming, and single-word comprehension
Logopenic	Anomia and reduced repetition ability

95

Particularly for rare neurodegenerative conditions, accurate and efficient

96 assessment is critical to formulate a diagnosis, establish the effects of intervention, and

97 monitor decline [8,11,13,14]. There is a need for direct assessment of functional

98 communication (FC) in people with dementia [15] and PwPPA [16], particularly as this

skill relates to early detection and designing optimal plans for intervention [13]. Early

100 detection and treatment approaches also rely upon the identification of and distinction

101 between the variant-specific impact on FC. Therefore, we have set out to develop a

102 standardized checklist for FC, and in this paper present our protocol for this project. This 103 study protocol centers on advancing assessment practices of FC for PPA, a critically 104 important aspect of supporting activities of daily living, autonomy, and therapeutic 105 intervention [7]. FC is interactive and contextual [7], yet traditional assessments of 106 speech and language are not interactive and do not generalize to natural conversation 107 [11,17]. As such, the current inventory of tools developed to capture and characterize FC 108 decline in PPA is insufficient [8,16,17]. 109 Therefore, the aim of this project is to create and validate an interactive tool to 110 capture clinically relevant aspects of FC for people living any of the three variants of 111 PPA (PwPPA). The primary outcome of this work will be the FC Checklist (FCC), a 112 novel instrument to capture and track strengths-based change in FC ability. The FCC's 113 quantitative outcomes for speech, language, and communication performance create a 114 common language that allows for cross-domain comparisons and consistency across 115 evaluators and sites. The FCC will enable clinicians to quantify FC in a systematic and 116 trackable manner and make appropriate and justified therapeutic recommendations [18]. 117 The FCC will also serve as a research tool, providing more nuanced insight into the 118 trajectory of a person's cognitive-linguistic performance and impact on overall 119 functioning, with the opportunity to provide participants with meaningful research 120 outcomes. Moreover, clinicians and researchers will be able to use the FCC as a tool to 121 provide valuable information to patients, care partners, and other providers to understand 122 and actively engage with plans of care [14,19,20]. 123 While some screening tools have been developed (e.g., the *Mini Linguistic State*

124 *Examination*) [21], traditional aphasia instruments lack sensitivity to detect mild or early-

125 stage PPA and fail to holistically evaluate FC ability [22]. Effective FC may be verbal, 126 text-based, non-verbal, or multimodal [7]; however, few existing assessment tools 127 examine non-verbal communication and instead focus on the other modalities in 128 isolation. These tools thus fail to examine multimodal interaction—a crucial feature of 129 day-to-day FC [22]. As such, there is a critical need for holistic, multimodal, and 130 sensitive measures of FC ability, spanning clinical observation, quantification, and 131 patient self- report [9,12]. 132 We plan to develop a reliable tool that can be used over time and across 133 institutions and providers. There is an important tool in this space, the Progressive 134 Aphasia Severity Scale (PASS) [23]. The PASS was developed to capture decline across 135 domains of speech, language, and communication in PPA. While the PASS provides a 136 robust means of tracking change across an impressive range of linguistic domains, the 137 PASS's measurement of FC is restricted to a single item and is impairment-focused. 138 Impairment-focused assessments are restrictive in that impairments are unreliable

139 predictors of a person's functional success [18,20,24]. In contrast, employing a strengths-

140 based and person-centered approach reframes the patient as an active agent in their life

141 [24] by capitalizing on their capabilities and their role in daily functioning

142 [7,8,11,24,25]—a critical shift that is necessary to enhance the individualized and

143 operationalized impact of clinical care. Finally, PwPPA report that most assessment

144 protocols are time consuming and burdensome [11,14,25]. Minimizing assessment

- burden for people living with neurodegenerative conditions, such as PPA, is crucial to
- 146 maintain trust and deliver respectful and patient-oriented care [11,14,25]. As such, there

147	is a sig	gnificant need for a person-centered, strengths-based, and minimally taxing
148	measu	re of FC. We propose that the FCC will meet this need.
149 150	2	Materials and Methods
151	2.1	Study Objectives
152	1.	Tool Development: curate an expert-validated clinical assessment tool of FC for
153		PwPPA.
154	2.	Tool Implementation: establish interrater reliability and validation of quantified
155		scores of FC.
156		<insert 1="" figure=""></insert>
157		Figure 1. Study Flow.
158	2.2	Ethics Approval
159		Approval for the study entitled "Assessment of Communicative Ability in
160	Alzhe	imer's Disease and Related Dementias" (STUDY00019344) was granted by the
161	Unive	rsity of Washington's Internal Review Board (IRB) on January 2nd, 2024.
162	2.3	Tool Development
163	2.3.1	Participants
164		At least fifty speech-language pathologist (SLP) experts will be identified and
165	recruit	ted through the International SLT/P PPA Network
166	(https:	//speechtherapyppa.builtbyknights.com/) as well as through a PubMed search for
167	resear	chers with recent publications on FC in adults with neurodegenerative conditions.

168 2.3.2 Experimental Approach

169 The purpose of the FCC is to broadly address whether specific features of speech, 170 language, and nonverbal communication present as strengths or interferences in FC. To 171 meet this purpose, item selection for the FCC will be guided by the methodological 172 framework proposed by Kirshner & Guyatt (1985) [18]. As a conduit for appropriate 173 clinical recommendations, which includes referral to speech and language services, the 174 FCC must be an index that is (1) discriminatory [18], to distinguish people with and without FC challenges and (2) evaluative [18], to facilitate a level of sensitivity that 175 176 captures change longitudinally in speech, language, and non-verbal communication. To 177 ensure that the FCC meets the primary purpose in the context of this year-long award, we 178 will use an electronic Delphi consensus process [26-28], consistent with the CREDES 179 best practices [26] and technical recommendations [27,28] (see prototype generated in 180 Phase One in Table 2 and Figure 1, Phases 3 and 4). The Delphi procedure is a structured 181 technique to form consensus using collective intelligence [26-28]. To conform to 182 standards, the procedure must be (1) anonymous, (2) able to actively engage a panel of 183 experts, (3) iterative, and (4) able to provide feedback in the form of response summaries 184 after each round [26-28]. The anonymity of web- enabled Delphi processes reduces 185 pressure to conform to group opinion [26-28]. 186 Delphi processes have three distinct stages. The first is *conceptualization* [26], 187 which entails defining the research goals, Delphi format, candidate FCC items, and 188 additional questions for panelists. This stage (as described in Phase One, Tool 189 Development in Figure 1) was conducted between February 21st and March 10th, 2024 190 and carried out by the panel of PPA experts (JG, JC, MLH, AM, BCS, and AV). The

191 second and third stages entail data collection and analysis (Phases 2 through 4, Tool 192 Development in Figure 1). For this proposal, in Phase 2 of Tool Development, at least 50 193 PPA and/or FC experts from around the world will be invited to participate in iterative 194 rounds of an online Oualtrics^{XM} [29] survey to establish rank order and rationales for the 195 inclusion of each of the FCC items. Expert selection will be guided by the 196 epistemological approach offered by Mauksch et al. (2020) [30], with a focus on panelist 197 familiarity and expertise. In each round, participants will be asked to rank existing FCC 198 items based on their clinical relevance and provide additional or alternative items to best 199 evaluate FC in PPA. Participants will also be given the opportunity to explain their 200 rationales and feedback for each FCC item. To minimize individual and collective bias, 201 the survey introduction will draw explicit attention to possible biases [28]. Phases 3 and 4 202 of Tool Development will occur iteratively until closing criteria have been met (see

203 below).

204 2.3.3 Statistical Analysis

205 We will implement a mixed-methods approach of qualitative and quantitative 206 analyses to evaluate panelist feedback. Panelists will receive aggregate descriptive 207 outcomes of rank order and general inclusionary/exclusionary rationale after each round, 208 as well as summaries of qualitative suggestions for additional or alternative items. This 209 feedback will explain item ranking per FCC constituent and the resulting modification of 210 the checklist items. Closing criteria will consist of a minimum of 80% consensus for 211 inclusion of FCC items [26-28] with statistical stability (insignificant difference in item 212 consensus) over the minimum of four rounds [26] of the survey. Following the final round of the Delphi procedure, panelists will receive the comprehensive statistical 213

214 analyses and results. Investigator JG and Co-Investigators PKC and RJF will code the 215 qualitative feedback by content type (e.g., rank order rationale, rationale for proposed 216 alternative/revised item, etc.) using Dedoose qualitative coding software [31] with 217 acceptable interrater reliability of 80% or higher [28]. 218 We will then utilize a qualitative "memo-ing" process based on the Grounded 219 Theory model of qualitative inquiry [32] to summarize themes within each content type. 220 Investigator JG and Co-Investigators PKC and RJF will independently summarize themes 221 and subsequently meet to discuss and reconcile differences in interpretation and achieve 222 consensus. For descriptive statistics, arithmetic mean values and standard deviations will 223 be calculated. Interquartile ranges will be used to assess consensus. Bipolarity analyses 224 will be conducted to examine whether there are sub-group differences despite in-group 225 consensus. Finally, outlier analyses will be conducted to detect whether there are 226 differential interpretations of certain items due to statement comprehensibility or other 227 reasons revealed in the qualitative feedback. 228 2.4 **Tool Implementation** 229 **Participants** 2.4.1 230 2.4.1.1 SLPs

After the FCC has been finalized by meeting closing criteria of the Delphi procedure, 15 SLPs who were not involved in developing the FCC and who have specialization in PPA will be recruited to pilot the checklist to rate FC based on the discourse samples from video recordings described below (see section 2.4.1.2 Video Curation). Expert SLPs will be recruited through the International SLT/P PPA Network [33], which has a reach of upwards of a hundred of relevant experts available to be

237 recruited for this purpose. Additionally, non-expert SLPs who work with adult 238 populations will be recruited through online forums and the University of Washington. 239 Participants will receive a one-time payment of \$100 for their participation in Phase 2 of 240 Tool Implementation. 241 2.4.1.2 PwPPA 242 We will recruit individuals that span the PPA spectrum, with three to four 243 examples of each of the three established variants [2], including heterogeneous profiles 244 [4,5], and five age-matched controls with typical cognition. The purpose of the control 245 group is to anchor the typical range of variability of communication. Participants will be 246 recruited from the University of Washington's Alzheimer's Disease Reach Center (UW 247 ADRC) and affiliated Memory and Brain Wellness Center. Numbers of unimpaired 248 participants are surpassed by the active cohorts of the UW ADRC's Clinical Core and 249 Registry. Eligible and interested participants will be consented to participate in an 250 identifiable video recording. Participants will receive a one-time payment of \$150 for 251 their participation in the assessment described in Phase 1, Tool Implementation. 252 2.4.2 Experimental Approach

253 2.4.2.1 Video Curation

Video recordings will be collected of PwPPA and controls using a procedure consistent with the validation process described for the *Clinical Dementia Rating* (CDR®), a global staging scale of individual domains [34,35]. The assessments will consist of three naturalistic discourse samples, elicited by a conversational in-take to establish the PwPPA's self-described strengths and needs, and one closed-ended and one open-ended discourse prompt prior to completing the *Quick Aphasia Battery* (QAB) [36]

260	to establish performance across domains of articulation, auditory comprehension, lexical
261	retrieval, motor function, reading, repetition, and semantic processing. Patient-reported
262	outcome measures will be gathered by asking PwPPA to rate the relative difficulty of the
263	discourse sample tasks using an aphasia-friendly, stakeholder-approved 5-point visual
264	scale ($0 =$ high burden, $4 =$ no burden) from the freely available, psychometrically
265	evaluated Aphasia Impact Questionnaire-concise (AIQ-concise) [37]. The AIQ-concise
266	scale offers a selection of gender and race visualizations to allow PwPPA to choose the
267	pictorial representations that closest align with their visualizations of self. Patient ratings
268	of perceived task-burden for the discourse tasks will be compared to those of the
269	comprehensive QAB to establish whether discourse-based tasks are perceived as less
270	burdensome.
271	2.4.2.2 FCC Implementation

272 In separate 45-minute online Zoom calls, the 15 SLPs will watch the participant 273 responses to the open and closed-ended discourse prompts. Following each case example, 274 the SLPs will be asked to fill out the FCC via a Qualtrics^{XM} [29] poll. SLPs will be asked 275 to simultaneously record their thought processes as they carefully consider the 276 applicability of each FCC item, consistent with the "Think Aloud" protocol [32,38,39]. 277 Application of the "Think Aloud" protocol will result in the collection of qualitative 278 targeted thinking to further refine the FCC. Two additional questions will be asked: (1) 279 How effective is this person's communication (1 = very effective, 5 = acceptable, 10 =280 ineffective) and (2) Rate the level of impairment of FC (0 = typical, 0.5 = questionable, 1281 = mild, 2 = moderate, 3 = severe). The latter question maps onto the PASS's "Functional 282 Communication" item [23], whereas the former allows for a "big picture" rating and how

283 this relates to the survey's other items. Following the completion of these Zoom calls, 284 results will be analyzed for item-level inter-rater reliability. Agreement between the 285 participant samples and "gold standard" ratings for each case example, generated by the 286 study team and expert panelist consensus, will also be analyzed. 287 We will then gather targeted feedback for the people assessed, providing the 288 person and people who want to communicate with them specific and evidence-based 289 recommendations to address areas of concern and improve FC. To generate this targeted 290 feedback [9,11,12,25] based on the FCC's structure, the study team will develop 291 informational guidance and clinical recommendations for each of the behaviors included. 292 The purpose is multifold and intended for patients, care partners, researchers, and 293 clinicians. In the context of a Zoom-based focus group, study team members will 294 generate concrete descriptions and guidance to address the possible interference posed by 295 each behavior described in the FCC (e.g., "word form" or "rate", see Table 2) 296 accompanied by publicly available and aphasia-friendly visuals [40]. Consistent with the 297 best practice principles for PPA [8] and expert recommendations, the feedback template 298 will explain the purpose of the discourse tasks collected in Phase 1, Tool Implementation, 299 contextualize the communication behavior outcomes, and provide tailored 300 recommendations to enhance FC. The feedback template will be made publicly available 301 online through the UW ADRC website for anyone to input FCC outcomes and receive 302 individualized guidance for strengths and relative interferences. 303

304 Table 2. Prototype of the Functional Communication Checklist established in Phase

305 1 in preparation for the anonymous Delphi Consensus process to be conducted in

306 **Phases 2 through 4.**

Functional Communication Checklist (Prototype, Version 1.5, 03/04/2024)					
	Inte				
COMMUNICATION CONSTITUENT	Mild	Moderate	Severe	NONE	
SPEECH (motor function and other acoustic properties that contribute to form)					
Voice/Resonance (breathiness/breath support, loudness)	1	2	3		
Articulatory precision (clarity of target speech sounds; speech distortions)	1	2	3		
Word form accuracy (do the words have speech sound errors?)	1	2	3		
Word production (absence of false starts and perseverations)	1	2	3		
Flow (absence of significant pausing)	1	2	3		
Prosody (use of pitch, phrase boundaries, and lexical stress)	1	2	3		
Rate of speech (appropriateness of speech tempo, i.e., not too fast or too slow)	1	2	3		
TOTAL					
Observed Strengths: Clinician-observed: Patient-reported:					
LANGUAGE (linguistic content: specificity, task relevance, and co	omprehensi	on)			
Specificity of word retrieval (does the speaker use underspecified/vague/empty language or specific/meaningful to refer to target words or concepts)	1	2	3		
Semantic accuracy (accuracy or appropriateness of word choice as it relates to meaning)	1	2	3		
Syntactic complexity (relative complexity of phrases in terms of type and length)	1	2	3		
Informativeness/topic completeness (does the speaker's point come across?)	1	2	3		

Circumlocution (does the speaker successfully speak around a topic or find alternative methods to describe them?)	1	2	3	
Comprehension of single words (concepts or actions)	1	2	3	
Comprehension of phrase-level output (statements, commands, or questions)	1	2	3	
TOTAL				

Clinician-observed:

Patient-reported:

DISCOURSE (language use in an interactive context))				
Establishing of topic (does the speaker clearly introduce their target topic?)	1	2	3		
Topic relevance (as based on context and/or prompt)	1	2	3		
Inclusion of story grammar elements (characters/agents, setting, actions, resolutions, and more)	1	2	3		
Cohesion and coherence (logical flow of utterances and ideas)	1	2	3		
Efficiency (how long does it take the speaker to communicate an intended idea using any modality?)	1	2	3		
 Functional success in interaction (success and efficacy in communicating an intended message based on typical daily activities; multiple should be used for scoring) <i>Examples:</i> How would you order your typical meal at your favorite restaurant? Please show me how you'd respond to an email or a text message from a friend. Can you explain to me what's troubling you about your language? 	1	2	3		
TOTAL					
Clinician-observed: Patient-reported:					
COGNITIVE CONTROL	<i>i</i>	ation)			
Initiation (purposeful and independent initiation of communicative participation)	1	2	3		
Inhibition (purposeful, voluntary restraint and adherence to expectations and sharing of content)	1	2	3		

Perception (identification and processing of relevant stimuli in immediate environment)	1	2	3	
Selective attention (attention to conversation partner and tasks)	1	2	3	
Sustained attention (maintenance of attention to conversation partner and tasks in this context)	1	2	3	
Working memory (maintenance and use of information provided in and relevant to current context)	1	2	3	
Long-term memory (maintenance, retrieval, and use of information prior to current context)	1	2	3	
TOTAL				

Clinician-observed:

Patient-reported:

SOCIAL-PRAGMATICS (social participation, engagement, and appropri	iateness)			
Participation in communicative context (engagement and initiation in communication, including but not limited to responding to the clinician, conversational turn-taking, and initiating topics or ideas)	1	2	3	
Initiation of communication repair strategies (independent implementation of strategies to smooth over communication breakdowns)	1	2	3	
Use of communication repair strategies when provided support (supported implementation of strategies to smooth over communication breakdowns)	1	2	3	
Social appropriateness of communication or participation (including but not limited to mirroring body language, maintaining expected comportment and engagement with clinician)	1	2	3	
Empathy or sensitivity to communication partner (recognition and responsiveness to clinician as a human and in terms of topic content)	1	2	3	
Use of body to explain or refer to objects, events, and actions (use of gestures, enactments, or visualizations to communicate intended meaning)	1	2	3	
Use of facial expression to enhance communication (use of facial expressions to communicate emotional state or feelings about content of a topic or situation)	1	2	3	
Use of prosody and intonation to enhance communicative intent (pitch and timing cues to indicate emotion, (dis)agreement, or grammatical content)	1	2	3	
Use of communication support to enhance communication (support is defined as AAC, writing, drawing, pointing to objects, objects, low and high tech (including but not limited to pictures, word books, and smart phones); also evaluate the strategic competence in	1	2	3	

flexibly switching between communication modalities to communicate an intended message)		
TOTAL		
Clinician-observed:		
Patient-reported:		

307

308 2.4.3 Statistical Analysis

309 These analyses are exploratory, with the goals of (1) understanding the 310 assessment items so that a future grant proposal can make any necessary improvements, 311 and (2) generating hypotheses for that project. To assess inter-rater item reliability, we will use the version of the kappa statistic that allows for different sets of raters. 312 313 Thresholds for acceptable kappa values vary, but we will consider a kappa of 0.60 to be 314 usable [41]. We are also aware of the "kappa paradox" that can arrive if a rater has low 315 sensitivity or specificity. Future work may involve forming summary measures for the 316 subdomains once items have been finalized. Qualitative feedback from the "Think 317 Aloud" procedure will be coded using Dedoose qualitative analytic software [31] by 318 study team members trained in qualitative analysis. This round of coding will apply a 319 fixed code for each FCC item discussed. Then, using the Grounded Theory-based 320 "memo-ing" process [32], three analysts will each independently review the feedback 321 associated with each FCC item, and draft a memo outlining issues/themes/concerns for 322 each. Analysts will subsequently meet to share and reconcile differences in interpretation 323 and achieve consensus regarding thematic content at the item level. The resulting final, 324 integrated memo will inform finalization of the FCC. The FCC is a formative measure

325 rather than assessing a latent trait, so a weighted score may or may not be advisable,

326 depending on how well the items correlate with each other and with overall function; for

327 certain individuals, strength in one item may be a prominent feature of FC, independent

- 328 of the presence or absence of other strengths.
- 329 2.5 Protection of Human Participants
- 330 2.5.1 Participants of Phase 1, Tool Implementation

331 Our goal for the proposed research is to recruit and enroll 9-10 individuals with a 332 diagnosis of PPA. The majority of individuals evaluated annually as part of the Clinical 333 Core program at the UW ADRC have also consented to being approached for additional 334 research studies. Participants eligible for the study will be patients who have received a 335 diagnosis of PPA by a neurologist (KDR), enrolled in the ADRC Clinical Core or UW 336 Memory and Brain Wellness Registry, and are able to comply with the experimental 337 protocol. Patients who cannot comply with the experimental protocol due to hearing, 338 English proficiency, vision, or cognitive impairment will be excluded. Similarly, patients 339 who do not consent to being video-recorded and having these recordings shared on UW 340 Sharepoint for educational purposes, accessible through the UW ADRC website, will also 341 be excluded.

Participants who respond positively to recruitment will be given a full explanation of the project by study staff. Per NIH policy, as a part of the informed consent process, we will also collect contact and demographic information from each of our PPA and control participants. Informed consent will be obtained from all people participating in this study, and all methods of recruitment and experimental protocols will be approved by the institutional review board of the University of Washington. Consent will be obtained

304690; this version posted March 24, 2024. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2024.03.21.24 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

348 from the participant or their legal representative, where the participant would at a 349 minimum provide assent. A copy of the signed consent form will be provided to all 350 enrollees.

351 2.5.2 Participants of Phases 3 and 4, Tool Development and Phase 2, Tool

352 Implementation

353 Our goal is to also recruit at least 65 SLPs with either expertise in PPA or general 354 knowledge in the assessment and care of adult populations. These SLPs will be recruited 355 through the University of Washington, national and international working groups, and 356 through online forums geared towards this target population. Exclusionary criteria will 357 include inability to commit to the time required for the experimental protocols for an 358 online survey (Phases 3 and 4, Tool Development) as well as dissent to being recorded 359 for those participating in Zoom videoconferencing calls (Phase 2, Tool Implementation). 360 The participant will be recruited through advertisement materials posted online and 361 through physical flyers. Each eligible participant will be provided with information 362 describing the purpose of the project, the experimental procedures, potential risks, and 363 benefits, and required time commitment. If the participant would like to participate, they 364 will receive an email to with an attachment for the informed consent documentation. 365 Each participant will receive a copy of the signed informed consent document, and the 366 original will be retained by the PI and stored on a secured Drive in Co-Investigator 367 KDR's lab.

368

2.5.3 Protection of Participant Data

369 Participant information as well as behavioral data will be collected according to 370 the procedures described within Materials and Methods. The data will consist of

371 clinical assessments as well as acoustic signals and digital video recorded during study 372 visits. Participant information, such as participant histories and clinical assessments, will 373 be recorded by entering the data directly into an electronic data capture system. The 374 system used will be a secure, HIPAA compliant implementation of the REDCap 375 Research electronic data capture software, hosted by the UW ADRC. This web-based 376 data capture system is designed specifically for human participants research, and is used 377 by over 1,000 institutions worldwide. It provides audit trails for tracking data 378 manipulation and user activity. Access is controlled by a secure web authentication 379 system and SSL encryption, and will be limited to the PI, Co-Investigators, and other 380 IRB-approved study staff only. Behavioral language data will be stored here. The digital 381 video recorded during the study will be stored on a secure, password-protected drive 382 hosted by the UW Sharepoint. Access to study data on this drive will be limited to 383 approved and verified individuals. Paper records will be accessible only to the Co-384 Investigator, PI and IRB-approved study staff. Participant-identifiable information such 385 as the master list matching participant names to ID numbers will be stored for 5 years and 386 then destroyed. To maintain confidentiality of the participants and their records, 387 participants will be identified in all study records and computer files by a three-digit 388 sequential numeric code. 389 The master list matching participant names to ID numbers will be stored in a

390 password-protected and encrypted digital file that is only accessible to study staff. The 391 privacy and confidentiality of participants participating in this study will be protected at 392 all times. Study procedures, including the explanation of the study and informed consent 393 process, will take place in a private office space. Participants will be referred to

throughout study files only by an anonymized numerical code. All computer files
containing participant-identifiable information will be kept in secure, access-restricted,
encrypted digital storage; any physical files pertaining to study participants will be kept
locked in a file cabinet in the Co-Investigator's (KDR) lab. Only IRB-approved study
staff will have access to review study records. No sensitive information will be collected
during this study that would require reporting to state or local authorities.

400 2.5.4 Potential Risks

The potential risks to participants from participating in this research are minimal. All participants participating in Phase 1 of Tool Implementation will complete behavioral assessments at a single timepoint. However, the extent of potential fatigue is not beyond what may be experienced in any other daily activity. There is a potential risk for discomfort due to the physical environment of being tested in a private room while being recorded. To preempt this, all participants will receive ample transition time to the space to help them get comfortable and to prepare them for the actual assessment.

408 2.5

2.5.5 Protections Against Risks

409 All information about the participants will be kept confidential. To maintain 410 confidentiality of the participants and their records, each participant will be assigned an 411 identification number and referred to by this number. The master list matching participant 412 names to ID numbers will be stored in a locked cabinet that is only accessible to the PI 413 and Co-Sponsor. Only IRB-approved study staff will have access to the data. The records 414 will be kept for approximately 5 years after completion of the study. This period will be 415 needed to verify results prior to publication. The PI will be responsible for applying for 416 and maintaining full IRB approval. In addition, all project personnel will be required to

417 complete human participants training. The University of Washington's Federal-Wide 418 Assurance requires that all University of Washington research with human participants, 419 regardless of funding source, abide by the Belmont principles of respect, beneficence, 420 and justice and the federal regulations in 45 CFR 46. Further, it states that University of 421 Washington will provide initial and continuing education to personnel conducting 422 research with human participants to help ensure that these ethical standards are met. To 423 assist in this process, University of Washington has subscribed to the Consortium for IRB 424 Training Initiative in Human Subjects Protections (CITI). 425 To be certified for human participant research, key project personnel must 426 complete the CITI tutorial every three years; this training must be supplemented annually 427 through CITI refresher tutorials or through attendance at one or more educational 428 sessions held by the IRB. Records verifying the completion of the above training for all 429 individuals will be maintained by Co-Investigators KDR and PKC. Participants in Phase 430 1 of Tool Implementation will be closely monitored by study staff during the study for 431 fatigue, discomfort, or any other adverse events. The PI will be responsible for the 432 reporting of any adverse events that occur over the course of the study. Adverse event 433 reporting will be done according to the guidelines of the University of Washington's 434 Human Subjects Division and our IRB. All major and minor adverse events will be 435 reported to the IRB. Should a participant express or show signs of discomfort or fatigue 436 that cannot be resolved with short periods of rest, the protocol will be terminated. No 437 special precautions are required before, during or after the study by the participant. 438 **2.5.6** Potential Benefits of the Proposed Research to Human Participants and 439 Others

440	For participants with PPA, we will provide information regarding the results of all
441	testing at the individual's request. This information may be useful for documenting
442	symptom progression and further explanation of their impact on daily participation and
443	communication.
444	3 Results
445	This study was approved for funding from the University of Washington's ADRC
446	in February 2024 following internal and external peer review (Awardee: JG, ADRC P30
447	grant, PI: Thomas J. Grabowski, MD). Phase One of Tool Development commenced
448	February 21 st , 2024. The results of the data analyses are expected to be available by
449	August 2025.
450	3.1 Dissemination
451	The authors will disseminate the results of this multitiered work through academic
452	and clinical conferences and peer-reviewed scientific journals. Results will also be
453	disseminated via stakeholder forums, including the monthly online Memory and Brain
454	Wellness newsletter and PPA Together! Support group. The authors will also develop
455	opportunities to disseminate outcomes of the study to people living with PPA, SLPs, and
456	researchers in collaboration with the National Aphasia Association PPA Task Force and
457	supported by the International SLT/P PPA Network.
458 459 460	4 Discussion
461	To date, there are no standard training materials that enable SLPs to develop
462	clinical expertise in PPA, nor frameworks to communicate assessment findings across
463	health professions, particularly as they pertain to FC ability. In this project, we propose to
464	develop a composite measure of FC that is structured as a simple rating scale and allows

465	clinicians to use a common framework to synthesize speech, language, and
466	communication function – regardless of the exact measurement tools used. Our aims are
467	two-fold, to improve both clinical and research practices of PPA assessment. Clear and
468	consistent agreement in behavioral ratings is paramount for appropriate clinical trial
469	recruitment, the implementation of therapeutic intervention, and monitoring change over
470	time. We will develop a series of tools that serve to train clinicians to assess PPA in
471	speakers from an informative participant sample, and to create a validated assessment
472	procedure to assess functional communication, which in turn provides the basis for
473	researcher, practitioner, patient, and care partner education. The outcomes of this work
474	will result in novel educational tools to cultivate comprehensive and resilience-oriented
475	assessment processes, as well as stakeholder tools to provide direct feedback to PwPPA.
476	Moreover, validation of the FC assessment will enhance collaboration and partnership
477	amongst healthcare providers and across institutions that serve this population.
478	5 Acknowledgements
479	This work is supported by the generous University of Washington's Alzheimer's
480	Disease Research Center Development Project Award (Awardee: JG).
481	6 Author Contributions
482	Conceptualization: Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.
483	Fredericksen
484	Data curation: Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.
485	Fredericksen
106	Eurodina acquisitions Iconno Collée

486 *Funding acquisition:* Jeanne Gallée

- 487 *Methodology:* Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.
- 488 Fredericksen, Aimee Mooney, Jade Cartwright, Maya L. Henry, Brielle C. Stark, Anna
- 489 Volkmer
- 490 *Investigation:* Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.
- 491 Fredericksen, Aimee Mooney, Jade Cartwright, Maya L. Henry, Brielle C. Stark, Anna
- 492 Volkmer
- 493 Formal Analysis: Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.
- 494 Fredericksen
- 495 Supervision: Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J. Fredericksen
- 496 *Writing original draft:* Jeanne Gallée
- 497 Writing review & editing: Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob
- 498 J. Fredericksen, Aimee Mooney, Jade Cartwright, Maya L. Henry, Brielle C. Stark, Anna
- 499 Volkmer

500 References

- What Is Frontotemporal Dementia, the Disease Bruce Willis Is Diagnosed With? |
 AFTD [Internet]. 2023 [cited 2024 Feb 20]. Available from:
- 503 <u>https://www.theaftd.org/posts/all-us-states/what-is-frontotemporal-dementia-the-</u>
- 504 <u>disease-bruce-willis-is-diagnosed-with/</u>
- Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et
 al. Classification of primary progressive aphasia and its variants. Neurology. 2011
 Mar 15;76(11):1006–14.

508	3.	Marshall CR, Hardy CJD, Volkmer A, Russell LL, Bond RL, Fletcher PD, et al.
509		Primary progressive aphasia: a clinical approach. J Neurol. 2018
510		Jun;265(6):1474–90.
511	4.	Ruksenaite J, Volkmer A, Jiang J, Johnson JC, Marshall CR, Warren JD, et al.
512		Primary Progressive Aphasia: Toward a Pathophysiological Synthesis. Curr
513		Neurol Neurosci Rep. 2021 Feb 4;21(3):7.
514	5.	Belder CRS, Marshall CR, Jiang J, Mazzeo S, Chokesuwattanaskul A, Rohrer JD,
515		et al. Primary progressive aphasia: six questions in search of an answer. J Neurol.
516		2024 Feb;271(2):1028–46.
517	6.	Ramsberger G, Rende B. Measuring transactional success in the conversation of
518		people with aphasia. Aphasiology. 2002 Mar 1;16(3):337-53.
519	7.	Doedens WJ, Meteyard L. What is Functional Communication? A Theoretical
520		Framework for Real-World Communication Applied to Aphasia Rehabilitation.
521		Neuropsychol Rev. 2022 Dec;32(4):937-73.
522	8.	Volkmer A, Cartwright J, Ruggero L, Beales A, Gallée J, Grasso S, Henry M,
523		Jokel R, Kindell J, Khayum R, Pozzebon M. Principles and philosophies for
524		speech and language therapists working with people with primary progressive
525		aphasia: An international expert consensus. Disability and Rehabilitation. 2023
526		Mar 13;45(6):1063-78.
527	9.	Kim SK, Park M. Effectiveness of person-centered care on people with
528		dementia: a systematic review and meta-analysis. Clinical Interventions in
529		Aging. 2017 Feb 17;12:381–97.

530	10. Hardy CJD, Taylor-Rubin C, Taylor B, Harding E, Gonzalez AS, Jiang J, et al.
531	Symptom-led staging for semantic and non-fluent/agrammatic variants of
532	primary progressive aphasia. Alzheimer's & Dementia. 2024;20(1):195-210.
533	11. Gallée J, Cartwright J, Volkmer A, Whitworth A, Hersh D. "Please Don't Assess
534	Him to Destruction": The R.A.I.S.E. Assessment Framework for Primary
535	Progressive Aphasia. Am J Speech Lang Pathol. 2023 Mar 9;32(2):391-410.
536	12. Fazio S, Pace D, Flinner J, Kallmyer B. The Fundamentals of Person-Centered
537	Care for Individuals With Dementia. The Gerontologist. 2018 Jan
538	18;58(suppl_1):S10–9.
539	13. Krein L, Jeon YH, Amberber AM, Fethney J. The Assessment of Language and
540	Communication in Dementia: A Synthesis of Evidence. Am J Geriatr Psychiatry.
541	2019 Apr;27(4):363-77.
542	14. Ho T, Whitworth A, Hersh D, Cartwright J. "They are dealing with people's
543	lives": Diagnostic and post-diagnostic healthcare experiences in primary
544	progressive aphasia. International Journal of Speech-Language Pathology. 2023
545	May 4;25(3):449–61.
546	15. Suárez-González A, Cassani A, Gopalan R, Stott J, Savage S. When it is not
547	primary progressive aphasia: A scoping review of spoken language impairment in
548	other neurodegenerative dementias. Alzheimer's & Dementia: Translational
549	Research & Clinical Interventions. 2021;7(1):e12205.
550	16. COMET Initiative Primary Progressive Aphasia: a Core Outcome Set for
551	improving intervention research [Internet]. [cited 2024 Mar 11]. Available from:
552	https://www.comet-initiative.org/Studies/Details/1871

553	17. Gallée J, Volkmer A. A Window Into Functional Communication: Leveraging
554	Naturalistic Speech Samples in Primary Progressive Aphasia. Perspect ASHA
555	SIGs. 2021 Aug 20;6(4):704–13.
556	18. Kirshner B, Guyatt G. A methodological framework for assessing health indices.
557	J Chronic Dis. 1985;38(1):27–36.
558	19. Hersh D, Boud D. Reassessing assessment: what can post stroke aphasia
559	assessment learn from research on assessment in education? Aphasiology. 2024
560	Jan 2;38(1):123–43.
561	20. Buntinx WH. Understanding disability: A strengths-based approach. The Oxford
562	handbook of positive psychology and disability. 2013 Aug 22:7-18.
563	21. Patel N, Peterson KA, Ingram RU, Storey I, Cappa SF, Catricala E, et al. A
564	'Mini Linguistic State Examination' to classify primary progressive aphasia.
565	Brain Communications. 2022 Apr 1;4(2):fcab299.
566	22. Matias-Guiu JA, Grasso SM. Primary progressive aphasia: in search of brief
567	cognitive assessments. Brain Communications. 2022 Oct 1;4(5):fcac227.
568	23. Sapolsky D, Domoto-Reilly K, Dickerson BC. Use of the Progressive Aphasia
569	Severity Scale (PASS) in monitoring speech and language status in PPA.
570	Aphasiology. 2014 Sep 2;28(8–9):993–1003.
571	24. McGee JS, McElroy M, Meraz R, Myers DR. A qualitative analysis of virtues
572	and strengths in persons living with early stage dementia informed by the values
573	in action framework. Dementia. 2023 Jan 1;22(1):46-67.
574	25. Loizidou M, Brotherhood E, Harding E, Crutch S, Warren JD, Hardy CJD, et al.
575	'Like going into a chocolate shop, blindfolded': What do people with primary

576		progressive aphasia want from speech and language therapy? International
577		Journal of Language & Communication Disorders. 2023;58(3):737–55.
578	26	Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting
579		and REporting DElphi Studies (CREDES) in palliative care: Recommendations
580		based on a methodological systematic review. Palliative medicine. 2017
581		Sep;31(8):684-706.
582	27	Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to
583		decide its appropriateness. World J Methodol. 2021 Jul 20;11(4):116–29.
584	28	Beiderbeck D, Frevel N, von der Gracht HA, Schmidt SL, Schweitzer VM.
585		Preparing, conducting, and analyzing Delphi surveys: Cross-disciplinary
586		practices, new directions, and advancements. MethodsX. 2021 Jan 1;8:101401.
587	29.	Qualtrics [Internet]. [cited 2024 Mar 4]. Qualtrics XM - Experience Management
588		Software. Available from: <u>https://www.qualtrics.com/</u>
589	30	Mauksch S, von der Gracht HA, Gordon TJ. Who is an expert for foresight? A
590		review of identification methods. Technological Forecasting and Social Change.
591		2020 May 1;154:119982.
592	31	Sociocultural Research Consultants LLC. (2023). Dedoose v.9.0.90. Retrieved
593		from www.dedoose.com. www.dedoose.com
594	32	Corbin J, Strauss A. Grounded theory methodology. Handbook of qualitative
595		research. 1994;17:273-85.
596	33	The International Speech and Language Therapy / Pathology Primary
597		Progressive Aphasia Network [Internet]. [cited 2024 Feb 20]. Available from:
598		https://speechtherapyppa.builtbyknights.com/

599	34. Morris JC. Clinical Dementia Rating: A Reliable and Valid Diagnostic and
600	Staging Measure for Dementia of the Alzheimer Type. International
601	Psychogeriatrics. 1997 Dec;9(S1):173-6.
602	35. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury
603	P. The Alzheimer's Disease Cooperative Study. Clinical Dementia Rating
604	training and reliability in multi-center studies: The Alzheimer's Disease
605	Cooperative Study Experience. Neurology. 1997;48:1508-10.
606	36. Wilson SM, Eriksson DK, Schneck SM, Lucanie JM. A quick aphasia battery for
607	efficient, reliable, and multidimensional assessment of language function. Jäncke
608	L, editor. PLoS ONE. 2018 Feb 9;13(2):e0192773.
609	37. Swinburn K, Best W, Beeke S, Cruice M, Smith L, Pearce Willis E, et al. A
610	concise patient reported outcome measure for people with aphasia: the aphasia
611	impact questionnaire 21. Aphasiology. 2019 Sep 2;33(9):1035-60.
612	38. Ericcson KA, Simon HA. Protocol analysis: Verbal reports as data (Rev. ed.).
613	Cambridge, MA: Bradford. 1993.
614	39. Wolcott MD, Lobczowski NG. Using cognitive interviews and think-aloud
615	protocols to understand thought processes. Currents in Pharmacy Teaching and
616	Learning. 2021 Feb 1;13(2):181-8.
617	40. ParticiPics – Aphasia Institute [Internet]. [cited 2024 Feb 20]. Available from:
618	https://www.aphasia.ca/participics/
619	41. McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica. 2012
620	Oct 15;22(3):276–82.
621 622	

1. Development



Figure 1